Guatemala has the largest pharmaceutical market in Central America. However, its per capita spending on medicines is among the lowest in the region (USD-- in ----). ...By ----, we forecast this to increase to --.- of healthcare spending and -.- of GDP. The commercial incentives for foreign drugmakers to further expand in Guatemala s pharmaceutical market are limited by the country s low per capita pharmaceutical spending and subdued market growth. However, in spite of this, the country will continue to attract investment as a regional pharmaceutical production hub and tax incentives are available to encourage foreign investment. The key risks to our projection are high levels of bureaucracy, corruption, the complex judicial system and low security due to non-political violence.
...Relations between Guatemala and Belize are likely to remain tense in the coming quarters, after a recent flare-up in the long-running territorial dispute between the two countries. This will temper cooperation on key economic and security policies and act as an additional deterrent for foreign companies considering investing in the disputed region. ...Relations between Guatemala and Belize are likely to remain tense in the coming quarters, after a recent flare-up in the long-running territorial dispute between the two countries. This will temper cooperation on key economic and security policies and act as an additional deterrent for foreign companies considering investing in the disputed region. The International Commission against Impunity in Guatemala s plan to crack down on local-level corruption in Guatemala will have only a modest near-term impact. ...The International Commission against Impunity in Guatemala s plan to crack down on local-level corruption in Guatemala will have only a modest near-term impact. Indeed, limited resources and a failure by Guatemalan legislature to put robust anti-impunity reforms in place will undermine the UN-backed body s efforts, ensuring that corruption will continue to undermine the operating environment in the years ahead.
...BMI s Risk/Reward Index (RRI) looks to provide a globally comparative and numerically based assessment of a market s attractiveness to innovative drugmakers looking to launch a new medicine in a country. In our Q--- RRI Guatemala maintains its score of --.- out of --- and moves up one position to --th place out of -- countries analysed in the Middle East and Africa (MEA) region. ...